Under construction – not a live service
Sign in
Taking people in ChinaPhase 1

LUCAR-G79D T cells for lupus and inflammatory muscle disease that returned

Tests LUCAR-G79D T cells in adults with returning lupus or muscle inflammation.

Plain-language title generated from the registry record
Registry title: A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

Key facts

Where
Bengbu, Changsha, Guangzhou, Nanchang, and Xuzhou, ChinaSee the 5 sites
Phase
Phase 1

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with systemic lupus erythematosus (SLE) or idiopathic inflammatory myopathies (IIM) that came back or did not respond to treatment, and whose cells test positive for CD19.

Age
18 to 70 years
Sex
Men and women can join.
Disease stage
SLE diagnosed at least 6 months before screening, or IIM diagnosed before screening. In both, the disease must be relapsed or refractory (came back or did not respond to treatment).
Biomarker or test result
Positive test for CD19. For SLE: positive antinuclear antibody and/or anti-dsDNA antibody and/or anti-Smith antibody. For IIM: positive test for myositis-associated or myositis-specific antibodies.

Main reasons for not taking part

  • Active infections such as hepatitis and tuberculosis
  • Other autoimmune diseases
  • Serious underlying diseases such as tumor or uncontrolled diabetes
  • Pregnant or breastfeeding women
  • History of major organ transplantation

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07331272, who can take part

Where in China

  • The Third The People's Hospital Of BengbuBengbu, ChinaContact: Hanwei WangTaking people
  • Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Hongjun ZhaoNot yet recruiting
  • Nanfang HospitalGuangzhou, ChinaContact: Qin HuangNot yet recruiting
  • The First Affiliated Hospital of NanChang UniversityNanchang, ChinaContact: Rui WuNot yet recruiting
  • The affiliated hospital of xuzhou medical universityXuzhou, ChinaContact: Dongmei ZhouTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Nanjing Legend Biotech Co.
Trial code
NCT07331272
Record updated
2 February 2026
Original description
This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.Read full original descriptionShow less

An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r/r SLE and r/r IIM.

Inclusion: Subjects voluntary agreement to provide written informed consent; Aged 18 to 70 years, either sex; Adequate organ function meet screening criteria; Positive test for cluster of differentiation antigen 19 (CD19); SLE:; Have been diagnosed of SLE at least 6 months before screening; At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive; Fulfill relapsed/refractory SLE conditions; IIM:; Have been diagnosed of IIM before screening; Positive test for myositis-associated antibodies or myositis-specific antibodies at screening; Fulfill relapsed/refractory IIM conditions.

Exclusion: Active infections such as hepatitis and tuberculosis; Other autoimmune diseases; Serious underlying diseases such as tumor, uncontrolled diabetes; Those with a history of major organ transplantation; Female subjects who were pregnant, breastfeeding.

ClinicalTrials.gov NCT07331272